髂股静脉术后支架内再狭窄因素的分析及处理

doi:10.16139/j.1007-9610.2024.06.04

摘要/Abstract

摘要：

髂股静脉支架植入术（IVS）是目前治疗各类急慢性深静脉阻塞疾病的一线治疗措施，有效改善临床症状。然而，IVS后发生支架内再狭窄（ISR）是影响支架通畅及造成再干预的主要原因。ISR是复杂的病理生理过程，与术前狭窄程度、病变特征、支架位置、支架受压程度、支架流入道面积以及其他生物学力学因素等多种危险因素有关。对于ISR的处理目前仍以球囊扩张为主要治疗手段，还应注重术后随访及监测，合理使用抗凝或抗血小板药物，把握合适的手术指征，根据病人情况选择合理的治疗方法。激光消融、动脉内膜切除装置以及放射治疗可能成为未来治疗ISR的新方法。

关键词: 髂股静脉支架植入术, 再狭窄, 危险因素

Abstract:

Iliofemoral venous stent placement (IVS) is currently the first-line treatment for various acute and chronic deep vein obstruction diseases, effectively improving clinical symptoms in patients. However, in-stent restenosis (ISR) after IVS is a major cause of stent-occlusion issues and re-intervention. ISR is a complex pathophysiological process related to multiple risk factors, including preoperative stenosis severity, lesion characteristics, stent position, stent compression, inflow area of the stent, and other biomechanical factors. Currently, the management of ISR primarily involves balloon dilation, it is also essential to emphasize postoperative follow-up and monitoring, rational use of anticoagulant or antiplatelet medications, appropriate surgical indications, and choosing the right treatment method based on patient conditions. Laser ablation, intravascular endarterectomy devices, and radiation therapy may become new options for ISR treatment in the future.

Key words: Iliofemoral venous stent placement(IVS), In-stent restenosis(ISR), Risk factor

中图分类号:

R543.6

续慧民, 高红霞. 髂股静脉术后支架内再狭窄因素的分析及处理[J]. 外科理论与实践, 2024, 29(06): 481-486.

XU Huimin, GAO Hongxia. Management of in-stent restenosis after iliofemoral venous stenting[J]. Journal of Surgery Concepts & Practice, 2024, 29(06): 481-486.

图/表 2

表1

表2

参考文献 46

[15]	ANNE L, YANNICK G, ELVIRA T, et al. Advances in stent technology for femoral artery lesions and use of stents for venous pathology[J]. Phlebolymphology, 2013, 20(4):174-180.
[16]	GASIOR P, CHENG Y, VALENCIA A F, et al. Impact of fluoropolymer-based paclitaxel delivery on neointimal proliferation and vascular healing: a comparative peripheral drug-eluting stent study in the familial hypercholestero-lemic swine model of femoral restenosis[J]. Circ Cardiovasc Interv, 2017, 10(5):e004450.
[17]	LI G, HU B, SUN Y, et al. Histological features of in-stent restenosis after iliac vein thrombus removal and stent placement in a goat model[J]. J Vasc Interv Radiol, 2024, 35(4):611-617. doi: 10.1016/j.jvir.2023.12.567 pmid: 38171414
[18]	YANG Y, ZHAO Y, CHEN Z, et al. The effect of stent compression on in-stent restenosis and clinical outcomes in iliac vein compression syndrome[J]. Quant Imaging Med Surg, 2021, 11(6):2245-2252.
[19]	RAJU S, DAVIS M. Anomalous features of iliac vein stenosis that affect diagnosis and treatment[J]. J Vasc Surg Venous Lymphat Disord, 2014, 2(3):260-267. doi: 10.1016/j.jvsv.2013.12.004 pmid: 26993384
[20]	CHO H, KIM J W, HONG Y S, et al. Stent compression in iliac vein compression syndrome associated with acute ilio-femoral deep vein thrombosis[J]. Korean J Radiol, 2015, 16(4):723-728. doi: 10.3348/kjr.2015.16.4.723 pmid: 26175570
[21]	DOI T, KAWARADA O, YAGYU T, et al. Iliac artery stent fracture associated with hip joint flexion[J]. Cardiovasc Interv Ther, 2019, 34(2):180-181. doi: 10.1007/s12928-018-0525-x pmid: 29730852
[22]	ANDREWS R T, VENBRUX A C, MAGEE C A, et al. Placement of a flexible endovascular stent across the femoral joint: an in vivo study in the swine model[J]. J Vasc Interv Radiol, 1999, 10(9):1219-1228.
[23]	YE K, LU X, JIANG M, et al. Technical details and clinical outcomes of trans popliteal venous stent placement for postthrombotic chronic total occlusion of the iliofemoral vein[J]. J Vasc Interv Radiol, 2014, 25(6):925-932.
[24]	ROSALES A, SANDBAEK G, JØRGENSEN J J. Stenting for chronic post thrombotic vena cava and iliofemoral venous occlusions: mid-term patency and clinical outcome[J]. Eur J Vasc Endovasc Surg, 2010, 40(2):234-240.
[25]	HARTUNG O, LOUNDOU A D, BARTHELEMY P, et al. Endovascular management of chronic disabling ilio-caval obstructive lesions: long-term results[J]. Eur J Vasc Endovasc Surg, 2009, 38(1):118-124.
[1]	BAI H, KIBRIK P, SHAYDAKOV M E, et al. Indications, technical aspects, and outcomes of stent placement in chronic iliofemoral venous obstruction[J]. J Vasc Surg Venous Lymphat Disord, 2024, 12(5):101904.
[2]	TAHA M A H, BUSUTTIL A, BOOTUN R, et al. A clinical guide to deep venous stenting for chronic iliofemoral venous obstruction[J]. J Vasc Surg Venous Lymphat Disord, 2022, 10(1):258-266.e1.
[3]	SALEEM T, BARRY O, THAGGARD D, et al. Iliac vein stent failure in community practice and results of corrective reinterventions[J]. J Vasc Surg Venous Lymphat Disord, 2023, 11(3):525-531.e3. doi: 10.1016/j.jvsv.2022.12.007 pmid: 36603688
[4]	DE MAESENEER M G, KAKKOS S K, AHERNE T, et al. Editor's choice - European society for vascular surgery (ESVS) 2022 clinical practice guidelines on the management of chronic venous disease of the lower limbs[J]. Eur J Vasc Endovasc Surg, 2022, 63(2):184-267.
[5].	RIZVI S A, ASCHER E, HINGORANI A, et al. Stent patency in patients with advanced chronic venous disease and nonthrombotic iliac vein lesions[J]. J Vasc Surg Venous Lymphat Disord, 2018, 6(4):457-463. doi: S2213-333X(18)30070-2 pmid: 29909853
[6]	SALEEM T, RAJU S. An overview of in-stent restenosis in iliofemoral venous stents[J]. J Vasc Surg Venous Lymphat Disord, 2022, 10(2):492-503.e2.
[7]	JAYARAJ A, NOEL C, KUYKENDALL R, et al. Long-term outcomes following use of a composite Wallstent-Z stent approach to iliofemoral venous stenting[J]. J Vasc Surg Venous Lymphat Disord, 2021, 9(2):393-400.e2. doi: 10.1016/j.jvsv.2020.08.020 pmid: 32827734
[8]	NEGLÉN P, RAJU S. In-stent recurrent stenosis in stents placed in the lower extremity venous outflow tract[J]. J Vasc Surg, 2004, 39(1):181-187. pmid: 14718837
[9]	NEGLÉN P, HOLLIS K C, OLIVIER J, et al. Stenting of the venous outflow in chronic venous disease: long-term stent-related outcome, clinical, and hemodynamic result[J]. J Vasc Surg, 2007, 46(5):979-990. doi: 10.1016/j.jvs.2007.06.046 pmid: 17980284
[10]	刘振斌, 王刚, 王博文, 等. 髂股静脉支架在髂静脉压迫综合征中的应用体会[J]. 血管与腔内血管外科杂志, 2024, 10(4):404-407,428.
	LIU Z B, WANG G, WANG B W, et al. Application experience of iliofemoral vein stenting in iliac venous compression syndrome[J]. J Vasc Endovasc Surg, 2024, 10(4):404-407,428.
[26]	KÖLBEL T, LINDH M, AKESSON M, et al. Chronic iliac vein occlusion: midterm results of endovascular recanalization[J]. J Endovasc Ther, 2009, 16(4):483-491. doi: 10.1583/09-2719.1 pmid: 19702343
[27]	YIN M, SHI H, YE K, et al. Clinical assessment of endovascular stenting compared with compression therapy alone in post-thrombotic patients with iliofemoral obstruction[J]. Eur J Vasc Endovasc Surg, 2015, 50(1):101-107.
[28]	ARDITA V, GALATI N, MIGLIORANZA E, et al. Endovascular treatment of chronic ilio-femoral vein obstruction with extension below the inguinal ligament in patients with post-thrombotic syndrome[J]. J Vasc Surg Venous Lymphat Disord, 2024, 12(3):101816.
[29]	NEGLÉN P, TACKETT T P Jr, RAJU S. Venous stenting across the inguinal ligament[J]. J Vasc Surg, 2008, 48(5):1255-1261. doi: 10.1016/j.jvs.2008.06.035 pmid: 18771877
[30]	CHENG C P, DUA A, SUH G Y, et al. The biomechanical impact of hip movement on iliofemoral venous anatomy and stenting for deep venous thrombosis[J]. J Vasc Surg Venous Lymphat Disord, 2020, 8(6):953-960. doi: 10.1016/j.jvsv.2020.01.022 pmid: 32321693
[31]	MACHADO H, SOUSA J, MANSILHA A. The impact of venous stenting across the inguinal ligament on primary patency: a systematic review[J]. Int Angiol, 2021, 40(4):270-276. doi: 10.23736/S0392-9590.21.04663-0 pmid: 33870677
[32]	JAYARAJ A, FULLER R, RAJU S, et al. In-stent restenosis and stent compression following stenting for chronic iliofemoral venous obstruction[J]. J Vasc Surg Venous Lymphat Disord, 2022, 10(1):42-51.
[33]	ZHOU Y, GUAN Y, XUE M, et al. Clinical outcomes of stenting extending below the inguinal ligament for treatment of chronic iliofemoral venous obstruction[J]. Ann Vasc Surg, 2021,75:259-266.
[34]	RAJU S, TACKETT P Jr, NEGLEN P. Reinterventions for nonocclusive iliofemoral venous stent malfunctions[J]. J Vasc Surg, 2009, 49(2):511-518. doi: 10.1016/j.jvs.2008.08.003 pmid: 18945579
[35]	ATTARAN R R, OZDEMIR D, LIN I H, et al. Evaluation of anticoagulant and antiplatelet therapy after iliocaval stenting: factors associated with stent occlusion[J]. J Vasc Surg Venous Lymphat Disord, 2019, 7(4):527-534. doi: S2213-333X(19)30151-9 pmid: 31203859
[36]	JALAIE H, ARNOLDUSSEN C, BARBATI M, et al. What predicts outcome after recanalization of chronic venous obstruction: hemodynamic factors, stent geometry, patient selection, anticoagulation or other factors[J]. Phlebology, 2014, 29(Suppl):97-103.
[37]	中国医师协会血管外科医师分会静脉学组. 常见静脉疾病诊治规范(2022年版)[J]. 中华血管外科杂志, 2022, 7(1):12-29.
	Phlebology Group of Vascular Surgery Physicians Branch, Chinese Physicians Association. Diagnosis and treatment standard of common venous diseases (2022 version)[J]. Chin J Vasc Surg, 2022, 7(1):12-29.
[38]	GUO B, CHEN C, LI Y, et al. Principles of optimal antithrombotic therapy for iliac venous stenting (POATIVES): a national expert-based Delphi consensus study[J]. J Vasc Surg Venous Lymphat Disord, 2024, 12(2):101739.
[39]	ABOU ALI A N, AVGERINOS E D, CHAER R A. Role of venous stenting for iliofemoral and vena cava venous obstruction[J]. Surg Clin North Am, 2018, 98(2):361-371. doi: S0039-6109(17)30231-1 pmid: 29502777
[40]	RAJU S, KNIGHT A, BUCK W, et al. Caliber-targeted reinterventional overdilation of iliac vein wallstents[J]. J Vasc Surg Venous Lymphat Disord, 2019, 7(2):184-194. doi: S2213-333X(18)30331-7 pmid: 30771830
[41]	JAYARAJ A, FULLER R, RAJU S. Role of laser ablation in recalcitrant instent restenosis post iliofemoral venous stenting[J]. J Vasc Surg Cases Innov Tech, 2021, 7(2):298-301. doi: 10.1016/j.jvscit.2021.03.004 pmid: 33997578
[42]	ROBERTSON C, VARCOE R L, BLACK S, et al. Histopathology of iliocaval venous in-stent restenosis treated with directional atherectomy[J]. J Endovasc Ther, 2019, 26(5):742-746. doi: 10.1177/1526602819857240 pmid: 31218927
[43]	吕家颉, 张琳杰, 杨成昊, 等. 腔内减容技术治疗髂股静脉支架再狭窄回顾性对照研究[J]. 中国实用外科杂志, 2023, 43(12):1391-1397.
	LV J J, ZHANG L J, YANG C H, et al. A retrospective controlled study on endovascular debulking technology for the treatment of iliac femoral vein stent restenosis[J]. Chin J Pract Surg, 2023, 43(12):1391-1397.
[44]	TEIRSTEIN P S. Prevention of vascular restenosis with radiation[J]. Tex Heart Inst J, 1998, 25(1):30-33. pmid: 9566060
[45]	WONG F K, KWOK P C, NGAN R K, et al. Prevention of restenosis of central venous stricture after percutaneous transluminal angioplasty and endovascular stenting by brachytherapy[J]. Kidney Int, 1999, 55(2):742-743. pmid: 9987101
[11]	魏磊, 金星. 髂静脉支架置入术后支架闭塞的危险因素分析及临床预测模型构建[J]. 中国现代普通外科进展, 2024, 27(8):633-638.
	WEI L, JIN X. Analysis of risk factors for stent occlusion after iliac vein stenting and construction of a clinical prediction model[J]. Chin J Curr Adv Gen Surg, 2024, 27(8):633-638.
[12]	MEISSNER M H. Indications for platelet aggregation inhibitors after venous stents[J]. Phlebology, 2013, 28(Suppl 1):91-98.
[13]	WILLIAMS D M, NICKLAS J M, OBI A, et al. Pathologic characteristics of human venous in-stent stenosis and stent occlusion[J]. J Vasc Surg Venous Lymphat Disord, 2023, 11(1):109-118.e2.
[14]	SEIJI K, TSUDA M, MATSUHASHI T, et al. Treatment of in-stent restenosis with beraprost sodium: an experimental study of short- and intermediateterm effects in dogs[J]. Clin Exp Pharmacol Physiol, 2009, 36(12):1164-1169.
[46]	KWOK P C, WONG K M, NGAN R K, et al. Prevention of recurrent central venous stenosis using endovascular irradiation following stent placement in hemodialysis patients[J]. Cardiovasc Intervent Radiol, 2001, 24(6):400-406.

ISR病变	软病变	硬病变
病因	血栓覆盖支架引起	由胶原蛋白组成的纤维性病变，可能发生钙化
病变位置	可延伸至支架的流入道	通常不会延伸至支架的流入道
发生时间	在支架植入后早期发生	在支架植入后晚期发生
血管内超声表现	较低回声	较强回声
复发倾向	较小	较大
病变特征	临床症状复发较少，对球囊扩张的抵抗较小	临床症状复发较多，对球囊扩张的抵抗较大
发生机制	流入/流出道问题，需纠正	与流入/流出道问题无关
治疗方法	血管成形术有助于改善狭窄情况	激光消融或内膜切除术对难治性病例有帮助

疾病类型	治疗阶段	推荐方案	疗程	推荐等级	一致性等级
NIVLs	初始阶段	抗凝药物±抗血小板药物	1个月	A	Ⅰ
	初始阶段	推荐低分子肝素或新型口服抗凝药作为初始抗凝药物	1个月	A	Ⅲ
	维持阶段	单独抗凝治疗或单独抗血小板治疗	未明确	C	Ⅲ
	维持阶段	推荐使用直接口服抗凝药作为优选抗凝药物	未明确	A	Ⅲ
急性髂股深静脉血栓	初始阶段	治疗剂量抗凝±抗血小板药物	1个月	A	Ⅲ
	初始阶段	如果选择抗凝加抗血小板药物	≥6个月	A	Ⅲ
	维持阶段	治疗剂量DOAC	至少6个月	A	Ⅳ
PTS	初始阶段	治疗剂量DOAC±抗血小板药物	1个月	A	Ⅲ
	维持阶段	建议使用治疗剂量抗凝药物		A	Ⅲ
	维持阶段	建议使用直接口服抗凝药	≥12个月	A	Ⅳ